Key facts about Tovorafenib
What dosages is Tovorafenib available in?
Tovorafenib is available as a 100 mg oral tablet and a 25 mg/mL oral suspension.
What is Tovorafenib used for?
Tovorafenib is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with certain types of brain tumors.
How does Tovorafenib work?
Tovorafenib is a targeted cancer therapy that works as a pan-RAF kinase inhibitor. It blocks specific proteins (kinases) involved in cell growth, which helps to slow or stop the growth of cancer cells in tumors with certain genetic mutations.
How do I take Tovorafenib?
The recommended dose of Tovorafenib is based on body surface area and is taken by mouth once weekly, with or without food.
Is it safe for me to take Tovorafenib?
Tovorafenib is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.
Tovorafenib Common Side Effects
Common side effects of Tovorafenib:
- Rash
- Hair color changes
- Fatigue
- Viral infection
- Vomiting
- Headache
- Fever
- Dry skin
- Constipation
- Nausea
- Acne
- Upper respiratory tract infection
Tovorafenib Serious Side Effects
Serious side effects are rare with Tovorafenib. Contact your healthcare provider immediately if you experience any of the following:
- Bleeding problems, such as nose bleeds or bleeding from the tumor
- Skin reactions, including sensitivity to sunlight (photosensitivity)
- Liver problems
- Slowing of growth (height) in children
Effects of other drugs, drug classes and over-the-counter products on Tovorafenib
The following medications may interact with Tovorafenib:
- Moderate and strong CYP2C8 inhibitors
- Moderate and strong CYP2C8 inducers
- Certain CYP3A substrates
- Hormonal contraceptives
Who makes Tovorafenib?
Various FDA-approved generic manufacturers
Is Tovorafenib safe in pregnancy?
Based on findings from animal studies and its mechanism of action, Tovorafenib may harm your unborn baby. Females of reproductive potential should use effective non-hormonal contraception during treatment and for 28 days after the last dose, since Tovorafenib can make some hormonal contraceptives ineffective. Male patients with female partners of reproductive potential should use effective nonhormonal contraception during treatment and for 2 weeks after the last dose.
